Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer

Abstract

Objective. To observe the effect of trastuzumab and cisplatin combined with irinotecan in the treatment of advanced Her-2 positive gastric cancer and its influence on disease control rate. Methods. From January 2018 to January 2021, 120 patients with advanced Her-2 positive gastric cancer admitted to our hospital were selected as the research subjects. According to the treatment plan of the patients, they were divided into a control group and a joint group, with 60 cases in each group; the control group was given trastuzumab + cisplatin, the joint group was treated with irinotecan on this basis, and the clinical effects and disease control rate of the two groups were observed. Results. After treatment, there were 4 patients with CR in the joint group and 0 patients with CR in the control group. The ORR and DCR of the joint group were significantly higher than those of the control group ( $P<0.05$ ). The expression levels of CA199, CEA, and CA724 after treatment in the two groups were significantly reduced ( $P<0.05$ ), and the reduction in the joint group after treatment was more evident as compared with the control group ( $P<0.05$ ). The joint group witnessed better memory function, physical function, behavioral function, emotional function, and communication function than the control group ( $P<0.05$ ), and the scores of all dimensions of the two groups of patients after treatment were superior to those before treatment ( $P<0.05$ ). The occurrence of side effects was not statistically different between the two groups of patients ( $P>0.05$ ). The 1-year survival rate of the control group was 41.67%, the PFS was 6.33 ± 1.02 months, and the OS was 15.51 ± 2.16 months; the 1-year survival rate of the joint group was 43.33%, and the PFS was 8.05 ± 1.07 months, and OS was 16.03 ± 2.44 months; there was no significant difference in the 1-year survival rate between the two groups ( $P>0.05$ ), the difference in PFS between the groups was significant (t = 9.013, $P<0.001$ ), and the difference in OS between the groups was not significant (t = 1.236, $P=0.219$ ). Conclusion. Trastuzumab + cisplatin combined with irinotecan yields a promising result in the treatment of advanced gastric cancer. It can effectively regulate the expression level of tumor markers, delay disease progression, and improve the quality of life of patients. Moreover, irinotecan will not bring more toxic side effects.